The Symptom Mismatch in Perimenopause: Why Nearly Four in Ten Women Report Being Misdiagnosed

“I just don’t feel like myself lately.”

It is one of the most common opening lines in midlife primary care, and one of the least diagnostically useful on its face. The patient is forty-four, sleeping badly, irritable in a way she describes as unfamiliar, and struggling to hold a thought through a meeting. Her cycles are still coming, roughly. She has read about perimenopause and dismissed the idea, because she is not having hot flashes.

Nearly four in ten women say the encounter that follows gets it wrong.

The size of the gap

A 2025 survey of women aged thirty to sixty (Biote Corporation, n=1,005) found that 39% felt they had been misdiagnosed when seeking care for perimenopausal symptoms. Anxiety and depression were commonly treated as free-standing conditions rather than assessed alongside the hormonal transition that may have been driving them.

The clinician side of the picture is equally instructive. Only 42% of clinicians initiated a discussion about perimenopause, and just 15% of women felt adequately informed when their symptoms began. Among women aged thirty to forty-four, 46% were never proactively asked whether they had experienced perimenopausal symptoms, and only 26% received information from their primary care physician or gynaecologist.

What women actually report

The mismatch at the centre of this is specific and measurable. In a 2026 peer-reviewed global digital survey of 17,494 women across 158 countries published in Menopause (Faubion SS, Shufelt CL, et al.), the following pattern emerged among the 12,681 respondents aged thirty-five and older:

Fatigue and mental exhaustion affect 83% of women in the transition. Severe irritability affects 80%. Depressive mood and anxiety affect 77%. Meanwhile 71% anticipate that hot flashes will be the hallmark that tells them perimenopause has begun.

Both the patient and the clinician are, in effect, waiting for a symptom that arrives late or not at all, while the symptoms that do arrive map neatly onto a psychiatric differential. The prescription that follows is often reasonable on the information available. The information available was incomplete.

Why FSH testing rarely settles it

Clinicians reaching for a laboratory answer usually reach for follicle-stimulating hormone, and in the perimenopausal window it performs poorly. The test gets ordered because it is what we have, the result comes back normal, and the patient leaves the office more confused than when she arrived. FSH fluctuates substantially cycle to cycle and within a single cycle during the transition, which means a value drawn on an arbitrary day describes that day rather than the patient’s stage. A normal result in a symptomatic forty-six-year-old is common and reassures nobody correctly.

The Stages of Reproductive Aging Workshop +10 (STRAW+10) criteria (Harlow SD, Gass M, Hall JE, et al., Menopause, 2012;19(4):387-395) remain the accepted staging framework, and they anchor the diagnosis in menstrual cycle changes rather than in hormone values. FSH is a supporting datum for late reproductive and late menopausal transition stages, not a decisive one, and STRAW+10 explicitly cautions against relying on it in the early transition where variability is highest.

The diagnosis in a woman over forty-five with characteristic symptoms and menstrual change is clinical. Laboratory testing earns its place in a narrower set of circumstances: suspected primary ovarian insufficiency under forty, an unclear picture where thyroid disease or anemia needs exclusion, or a patient on hormonal contraception where cycle history is uninformative.

Working through the differential

Presentation	Points toward perimenopause	Points elsewhere
Low mood and anxiety	New in the forties, fluctuating rather than persistent, tracks with cycle phase, accompanied by sleep disruption and cycle change	Present since the twenties, persistent rather than cyclical, anhedonia prominent, clear psychosocial precipitant
Fatigue	Worse after disrupted nights, improves on good sleep, coincides with cycle irregularity	Progressive regardless of sleep, weight change, cold intolerance, heavy menstrual bleeding
Cognitive complaints	Word-finding and working memory, fluctuating, no functional decline	Progressive, functional impairment, family concern, disorientation
Palpitations	Episodic, often nocturnal, no exertional pattern	Exertional, syncope, family history of sudden death
Joint pain	Diffuse, morning stiffness under thirty minutes, new in the transition	Synovitis, prolonged stiffness, inflammatory markers raised
Non-restorative sleep and daytime somnolence	Fragmented sleep with 2–4 a.m. wakening, tracks with vasomotor or hormonal symptoms, partner reports quiet sleep	Loud snoring, witnessed apneas, morning headache, resistant hypertension, elevated neck circumference, high STOP-BANG — consider obstructive sleep apnoea

Thyroid function, ferritin and a full blood count belong in almost every one of these workups. Their purpose is not to diagnose perimenopause but to remove the conditions that imitate it, and the two questions are frequently conflated.

How AI solves a data integration problem

The problem is not that we lack the knowledge to diagnose perimenopause well. The problem is that the knowledge is scattered across places our current systems do not connect: cycle-tracking apps the patient uses, wearable sleep and heart-rate data she checks daily, lab values from three different practices over four years, and a memory of how she felt eighteen months ago that no chart captures. The mismatch between the symptoms women experience and the diagnoses they receive is, at its root, a data integration problem dressed up as a clinical one.

A clinical decision support layer designed for this stage does five things that a fifteen-minute appointment structurally cannot.

• It assembles the trajectory before the visit begins. Perimenopause is defined by variability, which makes it structurally difficult to assess in the format we usually assess things: one appointment, one snapshot, one set of values. Cycle history, symptom logs, wearable-derived sleep architecture, resting heart rate drift, prior thyroid and ferritin and glucose values, and prescribing history are pulled into a single longitudinal view. What appears in the clinician’s summary is not the most recent number but the direction the numbers have been moving. A patient whose sleep has degraded over eighteen months, whose resting heart rate has drifted upward, and whose symptom pattern has become cyclical is describing a trajectory. The trajectory is the finding.
• It stages the patient against a recognized framework. STRAW+10, for example, gives us a reproducible way to describe where a woman is in the transition based on cycle characteristics, symptom pattern, and, where relevant, biomarker context. The infrastructure automates the staging so the clinician can confirm or override it rather than reconstruct it from scratch every visit. The physician remains the decision-maker; the platform removes the busywork.
• It surfaces the correlations that a single visit hides. When mood symptoms cluster in the luteal phase, when sleep fragmentation predicts the next irritable day, when a new joint complaint tracks with an emerging vasomotor pattern — these relationships live in the data. The infrastructure connects them, cites the peer-reviewed evidence behind the connection, and hands the pattern to the physician as a starting point for the conversation, not a conclusion.
• It flags the differentials that need to be ruled out. Obstructive sleep apnea, thyroid disease, iron deficiency, primary ovarian insufficiency, and — where relevant — the mood disorders that genuinely coexist with the transition rather than replace it as the diagnosis. Each flag traces back to the specific data point or symptom pattern that triggered it, and each is proposed to the physician as a hypothesis rather than declared as a finding. Physician-in-the-loop is not a caveat; it is the design.
• It gives the patient her own picture back. The same longitudinal record the clinician sees at the start of the visit is available to the patient in language she can read. What has changed. What has not. What we are watching. What we are ruling out. What the next check-in will look at. A woman who has spent three years being told her labs are normal experiences a different kind of visit when the record can show her what her labs have been doing, cycle by cycle, year over year. Feeling heard is downstream of feeling seen. Being seen requires infrastructure that can hold what a woman is experiencing across the years, not the fifteen minutes.

None of this replaces the clinician. All of it changes what the fifteen minute visit can accomplish. The attending decides. The infrastructure ensures the attending walks in with the whole picture rather than the most recent slice of it. In a diagnosis defined by direction of travel rather than by threshold values, that difference is the difference between the visit that gets it wrong and the visit that gets it right.

The solution

This is a large part of why we built the AI Clinical Decision Support tool Longevitix around continuity rather than around the visit. Symptom reports, laboratory results across years, prescribing history and wearable-derived sleep and heart rate trends are held as a single longitudinal record, and the summary a clinician sees at the start of an appointment reflects the direction of travel rather than the most recent value. Every conclusion the platform surfaces traces back to the data and the cited evidence behind it, which matters most in a diagnosis that is made from pattern rather than from a threshold.

For the patient who opens with “I don’t feel like myself lately”, a record that can show what she looked like eighteen months ago is worth more than any single test.